Cowen analyst Ritu Baral raised the firm’s price target on Sarepta to $125 from $114 and keeps an Outperform rating on the shares. The analyst said they pre-announced 4Q22 PMO revenues of 235.5M and FY22 of 843.3M on organic pt demand in the US. He thinks an AdComm is very likely for SRP-9001, especially if the BLA is potentially approvable although the company has not yet received any such confirmation by the FDA.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SRPT:
- UBS Says These 2 Stocks Offer Attractive Risk-Reward Right Now — Here’s Why
- Sarepta price target raised to $160 from $158 at Needham
- Sarepta price target raised to $114 from $101 at Credit Suisse
- Sarepta expects to exceed FY22 guidance for net product revenues
- Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
